Skip to Main Content

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel "Prime and Pull" Strategy

Conditions

Cervix

Phase II

What is the purpose of this trial?

To determine treatment efficacy defined as histologic regression to CIN 1 or less at weeks 20-24 (4 to 8 weeks after the end of imiquimod treatment) in the HPV Vaccine + Imiquimod group compared to control

  • Ages
    18 years and older
  • Gender
    Female only
  • Trial with
    Yale Cancer Center
  • Start Date
    06/12/2016
  • End Date
    03/30/2021
Trial Image

For more information about this study, contact:

Lisa Baker

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/19/2020
  • Study HIC
    #1603017415